Business Context and Reporting Period
This Form 8-K Current Report from Vanda Pharmaceuticals Inc. covers events occurring on April 23, 2019, with the report filed on April 24, 2019. The filing addresses corporate governance changes, specifically the election of a new director and the resignation of a current director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors from five to six effective April 23, 2019.
- New Director Election: Phaedra Chrousos was elected as a director, effective immediately. Her initial term expires at the 2021 annual meeting.
- Director Resignation: Vincent J. Milano notified the Board of his resignation as a Class II director, effective at the 2019 Annual Meeting of Stockholders.
- Board Reduction: Upon Mr. Milano's resignation, the Board size will be reduced from six back to five.
Compensation and Governance Details
Ms. Chrousos received the following compensation upon joining the Board:
- Initial Option Grant: 35,000 shares at an exercise price of $17.31 per share (closing price on April 23, 2019). Vesting is 25% after one year, with the remainder vesting monthly over three years.
- Annual Fee: $45,000 payable quarterly.
- Annual Awards: Eligible for an option to purchase 10,000 shares and a restricted stock unit award for 5,000 shares upon the conclusion of each annual meeting starting in 2019.
- Change of Control: All equity awards accelerate to 100% vesting in the event of a change of control.
- Independence: The Board determined Ms. Chrousos is an independent director.
Mr. Milano's resignation is voluntary to allow him to devote full time to other commitments. The Board will appoint a successor to his roles on the Audit Committee and as Chairman of the Compensation Committee.
Investor Verification Checklist
- Verify the exact date of the 2019 Annual Meeting of Stockholders to confirm the effective date of Mr. Milano's resignation and the subsequent reduction in Board size.
- Review the upcoming Definitive Proxy Statement for the 2019 annual meeting for full details on the outside director compensation program.
- Confirm the appointment of the successor to Mr. Milano's committee roles once announced.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.